Zentalis reports survival data from azenosertib ovarian cancer study

Data ReadoutazenosertibNeutral

AI Analysis

Summary

Zentalis Pharmaceuticals reported interim overall survival results from the DENALI Part 1b study of azenosertib in platinum-resistant ovarian cancer. The article excerpt does not disclose the specific survival figures.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Interim overall survival results reported from DENALI Part 1b study; specific results not provided in the article text.

Importance:6/10

Sentiment:

0.10

oncologyovarian cancerinterim dataoverall survivalDENALIazenosertibWEE1 inhibitor

Related Companies

$ZNTL

Read the original article

Published by Clinical Trials Arena on October 19, 2026 9:41 AM

Read Original